RECRUITING

Comparison of Whole Body DWI to FDG PET

Talk to us

Conditions

Metastatic CancerImaging Study

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Official Title

Comparison of Whole Body DWI to FDG PET Using PET/MRI

Quick Facts

Study Start:2025-02-06
Study Completion:2029-10-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06630845

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age ≥ 18 years.
  2. 2. Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI.
  3. 3. Ability to understand a written informed consent document, and the willingness to sign it.
  4. 4. Diagnosis of metastatic cancer.
  1. 1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
  2. 2. Individuals with contraindications to MRI. This will be determined through review of the UCSF MRI screening form by qualified site personnel

Contacts and Locations

Study Contact

Brad Kline
CONTACT
877-827-3222
brad.kline@ucsf.edu

Principal Investigator

Thomas A Hope, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Thomas A Hope, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-06
Study Completion Date2029-10-31

Study Record Updates

Study Start Date2025-02-06
Study Completion Date2029-10-31

Terms related to this study

Keywords Provided by Researchers

  • Imaging Study

Additional Relevant MeSH Terms

  • Metastatic Cancer